EXELIOM BIOSCIENCES – Trademark Portfolio
Entity Type: 34
EXELIOM BIOSCIENCES holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EXELIOM BIOSCIENCES.
67 rue des godrans
F-21000 Dijon
Showing of trademarks Trademarks
Trademark Classifications
EXELIOM BIOSCIENCES's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does EXELIOM BIOSCIENCES have?
EXELIOM BIOSCIENCES has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does EXELIOM BIOSCIENCES file in?
EXELIOM BIOSCIENCES files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are EXELIOM BIOSCIENCES's most well-known trademarks?
EXELIOM BIOSCIENCES's registered trademark portfolio includes well-known marks such as EXELIOM BIOSCIENCES. These are among 1 currently registered trademark in the portfolio.
What is EXELIOM BIOSCIENCES's trademark registration success rate?
EXELIOM BIOSCIENCES has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.